Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group.
In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.
Hook
E W
EW
University of Alabama at Birmingham and Jefferson County Health Department, 35294, USA.
McCormack
W M
WM
Martin
D
D
Jones
R B
RB
Bean
K
K
Maroli
A N
AN
D000284:Administration, Oral; D000293:Adolescent; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D020682:Cefixime; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000008:administration & dosage*; D024841:Fluoroquinolones; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D010403:Penicillin Resistance; D010879:Piperazines / Q000008:administration & dosage*; D015363:Quinolones / Q000008:administration & dosage*; D018440:beta-Lactam Resistance
D000890:Anti-Infective Agents; D002511:Cephalosporins; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; D020682:Cefixime; C075375:grepafloxacin; D002439:Cefotaxime